APA (7th ed.) Citation

X, W., & L, L. (2026). Efficacy and safety of vunakizumab in moderate-to-severe plaque psoriasis patients with different body mass index: A post hoc analysis based on a phase III trial. Frontiers in pharmacology, 16, 1685072. https://doi.org/10.3389/fphar.2025.1685072

Chicago Style (17th ed.) Citation

X, Wang, and Li L. "Efficacy and Safety of Vunakizumab in Moderate-to-severe Plaque Psoriasis Patients with Different Body Mass Index: A Post Hoc Analysis Based on a Phase III Trial." Frontiers in Pharmacology 16 (2026): 1685072. https://doi.org/10.3389/fphar.2025.1685072.

MLA (9th ed.) Citation

X, Wang, and Li L. "Efficacy and Safety of Vunakizumab in Moderate-to-severe Plaque Psoriasis Patients with Different Body Mass Index: A Post Hoc Analysis Based on a Phase III Trial." Frontiers in Pharmacology, vol. 16, 2026, p. 1685072, https://doi.org/10.3389/fphar.2025.1685072.